Mammoth Biosciences
Mammoth Biosciences is a biotechnology company developing CRISPR-based diagnostic and therapeutic technologies.
Last updated August 24, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Mammoth Biosciences is a privately held biotechnology company headquartered in Brisbane, California. Founded in 2017 by Jennifer Doudna, Janice Chen, Lucas Harrington, and Trevor Martin, the company was established around the use of CRISPR-associated enzymes for molecular diagnostics and genome editing. Its work combines CRISPR biology with metagenomics-based protein discovery, allowing the identification and characterization of compact enzymes that may be useful for detecting nucleic acids or modifying genetic material. The company initially became known for diagnostic applications of CRISPR, particularly its DETECTR technology. DETECTR uses CRISPR-associated enzymes to recognize particular DNA or RNA sequences and generate a detectable signal. In 2020, Mammoth was among the biotechnology companies adapting CRISPR-based detection methods to the COVID-19 pandemic. Its COVID-19-related diagnostic technology, marketed under the DETECTR BOOST trademark, was contracted for manufacture by Merck & Co., according to the company’s referenced history. The work placed Mammoth within a broader effort to develop faster, more accessible molecular testing methods outside conventional laboratory workflows. Mammoth also pursued industrial and research partnerships to extend its intellectual-property platform. In December 2019 and January 2020, it entered into agreements with Horizon Discovery concerning the combination of Mammoth’s CRISPR intellectual property with Horizon’s expertise in Chinese hamster ovary cells. The company later announced collaborations with Vertex Pharmaceuticals in 2021 and Bayer in 2022 to investigate compact CRISPR systems for in vivo genome editing. A central scientific focus of Mammoth’s platform is the discovery of ultra-small CRISPR enzymes, including CasΦ and Cas14. These systems are substantially smaller than the widely used Cas9 enzyme. Their compact size may make delivery into cells easier through viral and non-viral methods, including adeno-associated virus vectors. The systems may also offer useful biochemical characteristics, such as different protospacer adjacent motif requirements, potential allele-selective editing capabilities, and distinct off-target behavior. These features could expand the range of genetic targets that can be addressed, although their therapeutic utility depends on further research, validation, delivery development, and regulatory review. In 2023, Mammoth announced a strategic emphasis on CRISPR-based therapies, representing a shift in public emphasis from diagnostics toward therapeutic genome editing. The company’s positioning is therefore built around a discovery platform rather than a single consumer-facing product: it seeks to identify compact CRISPR systems and translate them into diagnostic tools, research applications, and medicines. Its commercial activities have included technology licensing, manufacturing arrangements, and collaborations with pharmaceutical and biotechnology companies. The company remains an active private biotechnology enterprise, while specific current executive leadership, product commercialization status, and financial information are not established in the supplied reference material.
History
Mammoth Biosciences was founded in 2017 by Jennifer Doudna, Janice Chen, Lucas Harrington, and Trevor Martin, drawing on research associated with the University of California, Berkeley and Stanford University. The company was created to commercialize and extend CRISPR biology beyond the best-known Cas9 system. Its founding concept combined enzyme discovery, molecular detection, and genome engineering, with the goal of identifying CRISPR systems that could be adapted for practical diagnostic and therapeutic use. The company’s early identity centered on CRISPR-based diagnostics. Its DETECTR approach uses CRISPR-associated enzymes to identify specific nucleic-acid sequences and produce a signal when a target is present. This model offered a potential alternative to conventional molecular testing workflows by combining sequence recognition with a programmable detection mechanism. Mammoth’s work became especially relevant during the COVID-19 pandemic, when the biotechnology sector explored rapid and scalable methods for detecting SARS-CoV-2. In 2020, Mammoth and Sherlock Biosciences were both associated with efforts to develop CRISPR-based coronavirus tests using different CRISPR technologies. Mammoth’s related technology was associated with the DETECTR BOOST trademark and was contracted to be manufactured by Merck & Co. Mammoth also developed commercial relationships intended to expand the uses of its platform. In December 2019 and January 2020, the company entered agreements with Horizon Discovery. The arrangements were described as combining Mammoth’s CRISPR intellectual property with Horizon’s capabilities in Chinese hamster ovary cells, a cell system widely used in biotechnology research and biomanufacturing. These agreements illustrated Mammoth’s broader strategy of working through partnerships rather than relying solely on internally developed products. A major scientific turning point came from the company’s metagenomics-based protein discovery platform. This work contributed to the identification and study of unusually compact CRISPR-associated enzymes, including members of the Cas14 and CasΦ families. Research on Cas14 described miniature enzymes capable of programmed DNA destruction, while work on CasΦ characterized a hypercompact genome editor derived from large bacteriophages. Such enzymes can be much smaller than Cas9, potentially allowing them to fit more readily into delivery systems used for genome editing. The therapeutic promise of these systems is linked to both size and targeting behavior. Smaller enzymes may be easier to package into viral vectors such as adeno-associated viruses, or to deliver using non-viral approaches. Their sequence-recognition requirements and editing profiles may also differ from those of Cas9. Possible advantages discussed for these systems include less restrictive protospacer adjacent motif requirements, the ability to address targets that are difficult to reach with larger nucleases, and potential allele-specific editing. These characteristics could be relevant to inherited diseases and other conditions in which precise genetic targeting is required. However, discovery of an enzyme does not by itself establish clinical safety or efficacy; therapeutic programs require extensive laboratory, animal, manufacturing, and regulatory development. Mammoth announced a partnership with Vertex Pharmaceuticals in 2021 and another with Bayer in 2022 to investigate ultra-small CRISPR systems for in vivo editing. These collaborations connected Mammoth’s enzyme-discovery capabilities with the disease-development and translational resources of larger pharmaceutical companies. In 2023, Mammoth publicly stated that it would focus on developing CRISPR-based therapies. This marked a strategic change in emphasis from the company’s earlier public profile, which had been strongly associated with diagnostics and pandemic testing. Mammoth’s current identity is that of a platform biotechnology company working at the intersection of molecular diagnostics, enzyme discovery, and therapeutic genome editing. Its history reflects the broader evolution of CRISPR commercialization: early diagnostic translation, rapid response to an infectious-disease emergency, partnerships for technology development, and a gradual move toward in vivo genetic medicines. The supplied reference material does not establish the company’s current executive roster, clinical-stage products, financial position, or the commercial status of each diagnostic and therapeutic program.
- 2023
Strategic focus on therapies
[1]The company announced a strategic emphasis on developing CRISPR-based therapies using ultra-small Cas enzymes.
- 2022
Bayer collaboration
[1]Mammoth announced a partnership with Bayer focused on the potential use of compact CRISPR systems in living organisms.
- 2021
Vertex collaboration
[1]Mammoth announced a partnership with Vertex Pharmaceuticals to research ultra-small CRISPR systems for in vivo editing.
- 2020
COVID-19 diagnostic development
[1]Mammoth adapted its CRISPR diagnostic technology for SARS-CoV-2 testing and associated the work with the DETECTR BOOST trademark.
- 2020
Publication on CasΦ genome editing
[3]Research characterized CasΦ as a highly compact CRISPR genome editor, reinforcing the potential importance of small nucleases for delivery-constrained applications.
- 2019
Agreement with Horizon Discovery
[1]Mammoth signed an agreement with Horizon Discovery to connect its CRISPR intellectual property with Horizon’s Chinese hamster ovary cell expertise.
- 2018
Publication on Cas14 miniature CRISPR enzymes
[2]Research involving Lucas Harrington and colleagues described programmed DNA destruction by miniature Cas14 enzymes, supporting the search for compact CRISPR systems.
- 2017
Company founded
[1]Jennifer Doudna, Janice Chen, Lucas Harrington, and Trevor Martin founded Mammoth Biosciences to develop CRISPR-based diagnostic and genome-editing technologies.
Products and positioning
A CRISPR biotechnology platform company focused on discovering compact genome-editing enzymes and translating them into molecular diagnostics and in vivo therapeutic applications.
CRISPR molecular diagnostics
DETECTR
DETECTR is Mammoth’s CRISPR-based nucleic-acid detection approach. It uses programmable CRISPR-associated enzymes to recognize target genetic sequences and produce a detectable signal. The platform was developed for molecular diagnostic applications and became particularly prominent during the search for rapid SARS-CoV-2 testing methods.
COVID-19 diagnostic technology · 2020
DETECTR BOOST
DETECTR BOOST is the trademark associated with Mammoth’s CRISPR-based COVID-19 diagnostic technology in the supplied reference material. The technology was developed during the 2020 pandemic response and was contracted to be manufactured by Merck & Co. The reference does not establish its current commercial availability.
Genome-editing discovery and therapeutic platform
Ultra-small CRISPR enzyme platform
Mammoth’s enzyme-discovery platform identifies compact CRISPR systems, including CasΦ and Cas14 family members. Their small size may support delivery through adeno-associated virus and other delivery systems, while their targeting properties may enable editing of genomic sites that are difficult to reach with larger nucleases. The platform is intended for therapeutic research and development rather than a single finished product.
Brand decisions
2023
Prioritize CRISPR-based therapeutic developmentStrategyBackground
Mammoth had built an early public profile around CRISPR diagnostics, including COVID-19 testing, while its research platform was also producing compact enzymes with potential genome-editing applications.
Action taken
The company announced that it would focus on developing CRISPR-based therapies, especially applications enabled by ultra-small Cas enzymes.
Aftermath
The announcement shifted the company’s strategic emphasis toward in vivo genome editing and therapeutic development. The supplied material does not provide clinical or financial outcomes.
2020
Develop COVID-19 testing technologyProduct launchBackground
The COVID-19 pandemic created demand for rapid molecular diagnostics, and CRISPR-based detection offered a programmable alternative to established testing methods.
Action taken
Mammoth applied its DETECTR technology to SARS-CoV-2 detection under the DETECTR BOOST trademark and arranged for manufacturing by Merck & Co.
Aftermath
The initiative expanded awareness of Mammoth’s diagnostic platform. The supplied sources do not establish the scale of deployment or subsequent commercial status.
Recent events
- 2023
Mammoth Biosciences shifts emphasis toward CRISPR-based therapies[1]
Other
The company announced that it would focus more strongly on developing therapeutic applications of CRISPR, including programs enabled by compact Cas enzymes.
- 2022
Mammoth and Bayer pursue ultra-small CRISPR systems[1]
Other
Mammoth announced a partnership with Bayer to research compact CRISPR systems for in vivo genome editing.
- 2021
Mammoth and Vertex collaborate on compact CRISPR editing[1]
Other
Mammoth announced a collaboration with Vertex Pharmaceuticals involving ultra-small CRISPR systems and their potential use in living organisms.
- 2020
DETECTR BOOST manufacturing arrangement for COVID-19 testing[1]
Product launch · Other
Mammoth’s CRISPR-based COVID-19 diagnostic technology, identified under the DETECTR BOOST trademark, was contracted for manufacture by Merck & Co.
- 2020
Mammoth and Horizon Discovery combine CRISPR and cell-engineering capabilities[1]
Other
Agreements announced in late 2019 and early 2020 connected Mammoth’s CRISPR intellectual property with Horizon Discovery’s expertise in Chinese hamster ovary cells.
Sources5 sources
- 1Mammoth Biosciencesen.wikipedia.org
- 2Programmed DNA destruction by miniature CRISPR-Cas14 enzymesdoi.org
- 3CRISPR-CasΦ from huge phages, is a hypercompact genome editordoi.org
- 4CRISPR–Cas12-based detection of SARS-CoV-2doi.org
- 5IDbyDNA Announces Engagement in United States Defense Advanced Research Projects Agency (DARPA) Program to Detect Threats using Gene Editing Technologiesprweb.com
Cite this profile: Cite the canonical profile. /brand-wiki/mammoth-biosciences · Editorial policy · How profiles are compiled